Literature DB >> 14750897

Liver tumor cryoablation: a commentary on the need of improved procedural monitoring.

Tom Mala1, Lars Aurdal, Lars Frich, Eigil Samset, Per K Hol, Bjørn Edwin, Odd Søreide, Iladhaug Gladhaug.   

Abstract

Cryoablation is a method used for in situ destruction of liver tumors not eligible for surgical resection. Local recurrences following such treatment have been reported at rates of 5-44%. Insufficient procedural monitoring of the ablation is one plausible explanation for these recurrences. The cryoablative procedure is usually monitored by ultrasonography, but acoustic shadowing and loss of signals, compromise visualisation of the cryolesion circumference. Other monitoring modalities such as computer tomography and invasive methods like the use of thermocouples and impedance measurements have also been studied, but are not in common clinical use as single monitoring modalities. Thermodynamic conditions assumed adequate for tumor eradication are likely to occur only in parts of the cryolesion. This tumoricidal part of the cryolesion is not adequately depicted using any of these modalities. Magnetic resonance imaging (MRI) provides a clear delineation of the cryolesion circumference. Noninvasive temperature measurements assisted by MRI indicate which parts of the cryolesion that may be subject to complete necrosis. In this article MRI monitored cryoablation of liver tumors is discussed. Improved peroperative monitoring as offered by MRI may reduce the rates of local recurrences after treatment, but further technological improvements are required.

Entities:  

Mesh:

Year:  2004        PMID: 14750897     DOI: 10.1177/153303460400300110

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  1 in total

1.  Laser-assisted cryosurgery in ex vivo mice hepatic tissue: viability assays using green fluorescent protein.

Authors:  L Martínez-Suástegui; B Duperray; F Godinez; G Guillén; A Slade; G Aguilar
Journal:  Ann Biomed Eng       Date:  2010-10-21       Impact factor: 3.934

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.